WO2001059429A1 - Flow cytometry for high throughput screening - Google Patents

Flow cytometry for high throughput screening Download PDF

Info

Publication number
WO2001059429A1
WO2001059429A1 PCT/US2001/006165 US0106165W WO0159429A1 WO 2001059429 A1 WO2001059429 A1 WO 2001059429A1 US 0106165 W US0106165 W US 0106165W WO 0159429 A1 WO0159429 A1 WO 0159429A1
Authority
WO
WIPO (PCT)
Prior art keywords
samples
flow cytometry
cytometry apparatus
sample
particles
Prior art date
Application number
PCT/US2001/006165
Other languages
French (fr)
Inventor
Larry Sklar
Bruce Edwards
Frederick Kuckuck
Original Assignee
The University Of New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/501,643 external-priority patent/US6890487B1/en
Application filed by The University Of New Mexico filed Critical The University Of New Mexico
Priority to AU2001243295A priority Critical patent/AU2001243295A1/en
Publication of WO2001059429A1 publication Critical patent/WO2001059429A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/08—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
    • G01N35/085—Flow Injection Analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
    • G01N35/1095—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices for supplying the samples to flow-through analysers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
    • G01N15/149—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G01N2015/1402—Data analysis by thresholding or gating operations performed on the acquired signals or stored data
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G01N15/1404—Fluid conditioning in flow cytometers, e.g. flow cells; Supply; Control of flow
    • G01N2015/1413—Hydrodynamic focussing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/0099—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor comprising robots or similar manipulators

Definitions

  • the present invention relates to a flow cytometry apparatus.
  • Flow cytometry is used to characterize cells and particles by making measurements on each at rates up to thousands of events per second.
  • the measurement consists of simultaneous detection of the light scatter and fluorescence associated with each event.
  • the fluorescence characterizes the expression of cell surface molecules or intracellular markers sensitive to cellular responses to drug molecules.
  • the technique often permits homogeneous analysis such that cell associated fluorescence can often be measured in a background of free fluorescent indicator.
  • the technique often permits individual particles to be sorted from one another.
  • a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles.
  • a method for analyzing a plurality of samples comprising: moving a plurality of samples comprising particles into a fluid flow stream; separating adjacent ones of the plurality of samples from each other in the fluid flow stream by a separation gas; and selectively analyzing each of the plurality of samples for the particles.
  • Figure 1A is a schematic view of a flow cytometry apparatus constructed in accordance with a preferred embodiment of the invention
  • Figure IB is a cross-sectional schematic view of immediately adjacent samples in a tube of the flow cytometry apparatus of Figure 1 A;
  • Figure 1C is a cross-sectional schematic view of buffer fluid separated adjacent samples in a tube of the flow cytometry apparatus of Figure 1 A;
  • Figure 2A illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using .02 inches inner diameter PharMed TM tubing in terms of a graph of Forward Scatter vs. Side Scatter;
  • Figure 3A illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using Tygon TM PVC tubing S-54-HL in terms of a graph of Forward Scatter vs. Side Scatter
  • particles refers to any particles that may be detected using a flow cytometry apparatus.
  • biomateriar refers to any organic material obtained from an organism, either living or dead.
  • the term ' ⁇ biomaterial "' also refers to any synthesized biological material such as synthesized oligonucleotides. synthesized polypeptides. etc.
  • the synthesized biological material may be a synthetic version of a naturally occurring biological material or a non-naturally occurring biological made from portions of naturally occurring biological materials, such as a fusion protein, or two biological materials that have been bound together, such as an oligonucleotide. such as DNA or RNA. bound to a peptide. either covalently or non-covalently. that the oligonucleotide does not normally bind to in nature.
  • peptide refers to all types of peptides and conjugated peptides including: peptides. proteins, polypeptides. protein sequences, amino acid sequences, denatured proteins, antigens, oncogenes and portions of onco ⁇ enes.
  • organism refers not only to animals, plants, bacteria, viruses, etc. but also to cell cultures, reproduced oligonuncleotides. etc. made from organic material obtained from animals, plants, bacteria, viruses, etc.
  • source well refers to any well on a well plate, whether or not the source well contains a sample.
  • sample source well refers to a source well containing a sample.
  • sample refers to a fluid solution or suspension containing particles to be analyzed using a method and/or apparatus of the present invention.
  • the particles to be analyzed in a sample may be tagged, such as with a fluorescent tag.
  • the particles to be analyzed may also be bound to a bead, a receptor, or other useful protein or polypeptide. or may just be present as free particles, such as particles found naturally in a cell lysate. purified particles from a cell lysate. particles from a tissue culture, etc.
  • the sample may include chemicals, either organic or inorganic, used to produce a reaction with the particles to be analyzed. When the particles to be analyzed are biomaterials.
  • drugs may be added to the samples to cause a reaction or response in the biomaterial particles.
  • the chemicals, drugs or other additives may be added to and mixed with the samples when the samples are in sample source wells or the chemicals, drugs or other additives may be added to the samples in the fluid flow stream after the samples have been intaken by the autosampler.
  • adjacent samples refers to two samples in a fluid flow stream that are separated from each other by a separation gas. such as an air bubble.
  • a separation gas such as an air bubble.
  • immediate adjacent samples refers to adjacent samples that are only separated from each other by a separation gas.
  • buffer fluid separated adjacent samples refers to adjacent samples that are separated from each other by two separation gas bubbles and a buffer fluid, with the buffer fluid being located between the two separation gas bubbles.
  • separation gas refers to any gas such as air, an inert gas. or fluid etc. that can be used to form a gas bubble or immiscible fluid between adjacent samples or between a sample and a buffer fluid.
  • An immiscible fluid is a fluid that will not substantially mix with and contaminate a sample.
  • buffer fluid refers to a fluid that is substantially free of the particles to be detected by the apparatus and method of the present invention.
  • a drug refers to any type of substance that is commonly considered a drug.
  • a drug may be a substance that acts on the central nervous system of an individual, e.g. a narcotic, hallucinogen, barbiturate, or a psychotropic drug.
  • a drug may also be a substance that kills or inactivates disease-causing infectious organisms.
  • a drug may be a substance that affects the activity of a specific cell, bodily organ or function.
  • a drug may be an organic or inorganic chemical, a biomaterial. etc.
  • the term “plurality "' refers to two or more of anything, such as a plurality of samples.
  • the term “homogenous” refers to a plurality of identical samples.
  • the term “homogenous” also refers to a plurality of samples that are indistinguishable with respect to a particular property being measured by an apparatus or a method of the present invention.
  • heterogeneous refers to a plurality of samples in a fluid flow stream in which there are at least two different types of samples in the fluid flow stream.
  • a heterogeneous plurality of samples in a fluid flow stream of the present invention may be obtained is by intaking different samples from different source wells in a well plate.
  • Another way of obtaining a heterogeneous plurality of samples is by intaking different samples from identical source wells at various time points where a reaction or a series of reactions is or had been occurring.
  • fluid flow stream refers to a stream of fluid samples, separated by one or more bubbles of a separation gas and/or one or more portions of a buffer fluid.
  • fluid flow path refers to device such as a tube, channel, etc. through which a fluid flow stream flows.
  • a fluid flow path may be composed of several separate devices, such as a number of connected or joined pieces of tubing or a single piece of tubing, alone or in combination with channels or other different devices.
  • high speed multi-sample tube refers to any tube that may be used with a peristaltic pump that has compression characteristics that allow a peristaltic pump to move samples separated by a separation gas through the tube at a speed of at least 6 samples per minute without causing adjacent samples to mix with each other.
  • An example of such a tube is a polyvinylchloride (PVC) tube having an inner diameter of about 0.01 to 0.03 inches and a wall thickness of about 0.01 to 0.03 inches.
  • PVC polyvinylchloride
  • a particularly preferred tube is a PVC tube having an inner diameter of about 0.02 inches and a wall thickness of about 0.02 inches.
  • the present invention uses a separation gas. such as air bubbles, to separate samples introduced from an autosampler into a tubing line that directly connects the autosampler and a flow cytometer.
  • a peristaltic pump between the two devices moves the fluid.
  • the air bubbles appear to be most effective at separating samples when there are no junctions or valves in the line. These junctions disturb or break up the bubbles and appear to allow the separated samples to come into contact with one another.
  • Peristaltic flow rates of ⁇ 3 ul /second through common tubing (0.02 inch tubing. 10 rpm or higher) have already been determined to be compatible with flow cytometric detection.
  • FIG. 1 A illustrates a preferred flow cytometry apparatus 100 of the present invention.
  • Flow cytometry apparatus 100 includes a conventional autosampler 102 having an adjustable arm 104 on which is mounted a hollow probe 106.
  • arm 104 moves back and forth (left and right in Figure 1 ) and side to side (into and out of the plane of Figure 1), probe 106 is lowered into individual source wells 108 of a well plate 110 to obtain a sample that has been tagged with a fluorescent tag (not shown in Figure 1) to be analyzed using flow cytometry apparatus 100. Once a sample is picked up by probe 106.
  • each of the two or more different types of samples may be tagged with different fluorescent tags, different amounts of a single tag or some combination of different tags and different amount of a single tag.
  • the groupings of data points will vary vertically on a fluorescence versus time graph, depending on which type of sample is being sensed.
  • each sensed sample will exhibit a group of data points aligned with the time that the sample passes through the laser interrogation point.
  • some of the source wells on the well plate of the apparatus illustrated in Figure 1A may contain a buffer solution to allow for the formation of buffer fluid separated adjacent samples in a tube through which samples pass.
  • the probe intakes air. then is lowered into a source well containing buffer solution, then the probe intakes air again, and then the probe intakes a second sample. This sequence may then be repeated for samples which the probe subsequently intakes.
  • Figure 1C shows how two buffer fluid separated adjacent samples 140 and 142 are separated from each other by buffer fluid 144 and two air bubbles 146 and 148 in tube 1 14. When samples 140 and 142 pass through laser interrogation point 122.
  • the groupings of data points will vary vertically on a fluorescence versus time graph, depending on which type of sample is being sensed. As with the case of sensing a single type of sample, each sensed sample will exhibit a group of data points aligned with the time that the sample passes through the laser interrogation point.
  • buffer fluid separated adjacent samples may be formed by providing a reservoir of buffer fluid in or attached to the autosampler to inject buffer fluid into the tube for the fluid flow stream.
  • the probe intakes air.
  • buffer fluid is injected into the tube for the fluid flow stream, then the probe intakes air again, and then the probe intakes a second sample. This sequence may then be repeated for subsequent samples to be separated by a buffer fluid.
  • the present invention is compatible with relatively inexpensive commercial well plates for use with autosamplers from 96 well plates to 384 well plates to at least as many as 1536 well plates.
  • the source wells of the present invention may be all filled with samples and/or buffer fluids, or some may be left empty.
  • the sample types may be arranged in the order in which they are taken up by the probe, or the sample types may be arranged in any other convenient arrangement. For example, all of the source wells in a one row of source wells may contain one sample type and all of the source wells of a second row may contain a second sample type.
  • the source wells may be made any conventional shape used for source wells in a well plate for an autosampler.
  • the source wells are conical in shape, as illustrated in Figure 1A. to allow even the smallest amounts of sample to be withdrawn by the probe or to allow the particles to concentrate in the bottom of the well.
  • the use of a well plate with conical source wells reduces the problems associated with the settling of particles to the bottom of the well prior to being intaken by the probe.
  • An alternative means to circumvent particle settling would be to sample from wells in an inverted plate given an appropriate well dimensions that will permit sample retention in the well (e.g. by capillary forces) when the plate is in this position.
  • the autosampler of the present invention may be any conventional autosampler suitable for intaking samples from a well plate.
  • a preferred type of autosampler is the Gilson 215 liquid manager.
  • One preferred probe for the present invention is a .01 inch ID. 1/15 inch OD stainless steel needle compatible with HPLC ferrule fittings.
  • a Gilson interface module for bidirectional communication between an MS DOS computer and a probe manipulating arm and peristaltic pump.
  • Software designed using commercial languages, such as Microsoft Visual C++, may be used to control the speed and distance of probe motions in all 3 dimensions, the sensing of probe contact with liquid in a source well to assure reproducible sample volumes, and the speed of the peristaltic pump.
  • a computer or other known device may be used to control the autosampler to regulate sample size and bubble size by varying the time that the probe is in a source well or above a source well.
  • sample handlers and sampler handling systems that may be useful in the apparatus and method of the present invention are well known in the art.
  • One example of an integrated handler and programmable station is the Beckman 1000 Laboratory Workstation TM robotic which may be adapted for use in the apparatus or method of the present invention.
  • the probe may have a conical tip.
  • Use of silicone or other hydrophobic agent to coat the tip of the sampling probe may also be helpful to minimize sample carryover.
  • the entire probe may be made of a hydrophobic material to reduce carryover. Suitable hydrophobic materials for used in the coating or for making the entire hydrophobic probe include: Teflon® (poly(tetrafluoroethylene) (PTFE)), Kynar ® (polyvinylidene fluoride). Tefzel ® (ethylene-tetrafluoroethylene copolymer).
  • PFA tetrafluoroethylene-perfluoroalkyl vinyl ether copolymer resin
  • EFP tetrafluoroethylene-hexafluoropropylene copolymer
  • PEEK polyether ether ketone
  • a jet of gas such as air
  • the source of the jet of gas may be mounted either on the autosampler or near the autosampler.
  • Another way to reduce sample carryover is to use a rinsing device that may be attached to the autosampler or be otherwise mounted on or near the flow cytometry apparatus of the present invention to rinse the autosampler probe between intakes of sample and/or buffer solution.
  • the rinsing fluid may be water, a mild detergent, or a solvent, such as a solvent in which each of the particles in one or more of the samples is dissolved.
  • the rinsing fluid may be the same as the suspension fluid.
  • the use of an autosampler with a sensing probe tip may improve the efficiency of sample uptake and performance by reducing carryover and ensuring reproducible sample volumes.
  • peristaltic pumps may be used with the flow cytometry apparatus of the present invention.
  • a preferred peristaltic pump is Gilson Minipuls 3.
  • a peristaltic pump of the present invention is operated in a manner that reduces pulsatile flow, thereby improving the sample characteristics in the flow cytometer.
  • a tubing length greater than 20 inches between pump and flow cytometer may be used or a linear peristaltic pump such as the Digicare LP5100 may be used to improve the sample characteristics.
  • tubing may be used for the fluid flow path of the present invention, as long as the tubing may function as high speed multi-sample tubing.
  • PVC polyvinyl chloride
  • the fluid flow path of the present invention is a single length of tubing without junctions. Such a single length of tubing reduces the breakup of bubbles and improves the performance in sample separation.
  • a preferred type of high speed multi-sample tubing for use with the present invention is 0.01 to 0.03 inch inner diameter PVC tubing having a wall thickness of 0.01 to 0.03 inches.
  • a particularly preferred tubing is 0.02 inch inner diameter PVC tubing having a wall thickness of 0.02 inch.
  • flow cytometers may be used with the flow cytometry apparatus of the present invention. Preferred types of flow cytometers are described in U.S. Patent Nos. 5.895.764; 5.824,269; 5.395.588; 4.661.913; the entire contents and disclosures of which are hereby incorporated by reference.
  • samples may be sorted on a particle by particle basis using known methods.
  • the flow cytometer may use software gating by light scatter to reduce the "noise " in the flow cytometer introduced by the periodic appearance of bubbles.
  • the use of the real-time software in conjunction with flow cytometer controlling software may allow the samples from a given source well to be re-checked during sampling and data analysis to prove that "hits" from neighboring source wells do not arise from cross-contamination.
  • On-line data analysis may be used in the flow cytometer to compare data between well plates and facilitate overall utility of the data in conjunction with automation. Operation of the flow cytometer at higher pressure generally increases the sample flow rate and may, in some circumstances yield a higher throughput. Also, operation of the flow cytometer with increased time resolution in data software may allow resolution of samples at higher throughput rates.
  • peristaltic pumps and air bubbles have been used in a variety of detection devices with flowing samples.
  • bubbles are commonly used in clinical instruments to separate samples and the peristaltic pumps to move fluids.
  • flow cytometry there is specific teaching against air bubbles with the idea that, optimally, the bubbles should be removed from the sample prior to injection into the flow cytometer.
  • the flow cytometry apparatus of the present invention it has already been possible to move and analyze at least 6 samples per minute.
  • the flow cytometry apparatus may be capable of moving and analyzing 60 samples per minute. even more preferably 120 samples per minute, and yet even more preferably 240 samples per minute.
  • a sample drawn into the fluid stream tubing at 10 ⁇ m and flowing at a rate of ⁇ 3 ul/sec requires less than a 2 ul sample.
  • the throughput of the flow cytometry apparatus of the present invention tends to be more affected by the behavior of the autosampler rather than the characteristics of the peristaltic pump, the tubing or the flow cytometer.
  • the throughput of the flow cytometry apparatus of the present invention tends to be more affected by the behavior of the autosampler rather than the characteristics of the peristaltic pump, the tubing or the flow cytometer.
  • higher throughputs are achieved.
  • Improved accuracy in volume intake/delivery by the autosampler leads to smaller sample volumes and improved throughputs.
  • FIG. 1A Using a flow cytometer apparatus set-up similar to that shown in Figure 1A, commercial peristaltic tubing with thick walls (PharMed TM; 0.02 inch inner diameter. 3.69 mm outer diameter, polypropylene elastomer) was compared with another type (0.02 inch inner and 0.06 inch outer diameter Tygon Microbore TM. formulation S-54- HL) that had thin walls and was considerably stiffer.
  • Figures 2A and 2B illustrate the flow cytometer results using the PharMed TM tubing to move samples 202. 206. 210, and 214 of Coulter Flow-Check beads having a proprietary fluorochrome as a fluorescence tag and four samples 204. 208. 212.
  • Figure 2A is a graph of Forward Scatter vs. Side Scatter with a gate around the particles aligned in the laser beam of the flow cytometer.
  • Figures 3 A and 3B illustrate the flow cytometer results using the PVC tubing to move samples 302, 306. 310. and 314 of Coulter Flow-Check beads having a proprietary fluorochrome as a fluorescence tag and four samples 304, 308, 312.
  • Figure 3A is a graph of Forward Scatter vs. Side Scatter with a gate around the particles aligned in the laser beam of the flow cytometer.

Abstract

The present invention provides a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: a means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles. The present invention also provides a flow cytometry method employing such an apparatus.

Description

FLOW CYTOMETRY FOR HIGH THROUGHPUT SCREENING
CROSS-REFERENCE TO RELATED APPLICATIONS
This application makes reference to co-pending U.S. Provisional Patent
Application No. 60/156.946. entitled "Flow Cytometry Real-Time Analysis of Molecular Interactions/" filed November 9. 1999. The entire contents and disclosure of this application is hereby incorporated by reference.
GOVERNMENT INTEREST STATEMENT
This invention is made with government support under contract number NIH 1R24 GM 60799 (Project Number 3). The government may have certain rights in this invention.
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to a flow cytometry apparatus.
Description of the Prior Art
Flow cytometry is used to characterize cells and particles by making measurements on each at rates up to thousands of events per second. The measurement consists of simultaneous detection of the light scatter and fluorescence associated with each event. Commonly, the fluorescence characterizes the expression of cell surface molecules or intracellular markers sensitive to cellular responses to drug molecules. The technique often permits homogeneous analysis such that cell associated fluorescence can often be measured in a background of free fluorescent indicator. The technique often permits individual particles to be sorted from one another.
However, a deficiency with conventional flow cytometry is that it does not allow for the analysis of multiple samples consisting of multiple cells or particles in a rapid manner, a fact that has limited the uses of flow cytometry in drug discovery. For example, the industrial standard for high throughput drug discovery is 100.000 samples per day. Because of its low throughput, flow cytometry has generally not been considered applicable to high throughput screening in drug discovery.
SUMMARY OF THE INVENTION
It is therefore an object of the present invention to provide a flow cytometry apparatus that meets the needs of high throughput screening.
According to one aspect of the present invention, there is provided a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles.
According to a second aspect of the present invention, there is provided a method for analyzing a plurality of samples comprising: moving a plurality of samples comprising particles into a fluid flow stream; separating adjacent ones of the plurality of samples from each other in the fluid flow stream by a separation gas; and selectively analyzing each of the plurality of samples for the particles. Other objects and features of the present invention will be apparent from the following detailed description of the preferred embodiment.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will be described in conjunction with the accompanying drawings, in which:
Figure 1A is a schematic view of a flow cytometry apparatus constructed in accordance with a preferred embodiment of the invention;
Figure IB is a cross-sectional schematic view of immediately adjacent samples in a tube of the flow cytometry apparatus of Figure 1 A;
Figure 1C is a cross-sectional schematic view of buffer fluid separated adjacent samples in a tube of the flow cytometry apparatus of Figure 1 A;
Figure 2A illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using .02 inches inner diameter PharMed TM tubing in terms of a graph of Forward Scatter vs. Side Scatter;
Figure 2B illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using .02 inches inner diameter PharMed TM tubing in terms of a graph of Fluorescence vs. Time (1024 channels = 60 seconds);
Figure 3A illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using Tygon TM PVC tubing S-54-HL in terms of a graph of Forward Scatter vs. Side Scatter; Figure 3B illustrates the results of an experiment using a flow cytometry apparatus similar to that shown in Figure 1A using Tygon TM PVC tubing S-54-HL in terms of a graph of Fluorescence vs. Time (1024 channels = 60 seconds).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
It is advantageous to define several terms before describing the invention. It should be appreciated that the following definitions are used throughout this application.
Definitions
Where the definition of terms departs from the commonly used meaning of the term, applicant intends to utilize the definitions provided below, unless specifically indicated.
For the purposes of the present invention, the term "particles"' refers to any particles that may be detected using a flow cytometry apparatus.
For the purposes of the present invention, the term "biomateriar refers to any organic material obtained from an organism, either living or dead. The term '■biomaterial"' also refers to any synthesized biological material such as synthesized oligonucleotides. synthesized polypeptides. etc. The synthesized biological material may be a synthetic version of a naturally occurring biological material or a non-naturally occurring biological made from portions of naturally occurring biological materials, such as a fusion protein, or two biological materials that have been bound together, such as an oligonucleotide. such as DNA or RNA. bound to a peptide. either covalently or non-covalently. that the oligonucleotide does not normally bind to in nature.
For the purposes of the present invention, the term "oligonucleotide*" refers to any oligonucleotide. including double and single-stranded DNA. RNA. PNAs (peptide nucleic acids) and any sequence of nucleic acids, either natural or synthetic, derivatized or underivatized.
For the purposes of the present invention the term "peptide"" refers to all types of peptides and conjugated peptides including: peptides. proteins, polypeptides. protein sequences, amino acid sequences, denatured proteins, antigens, oncogenes and portions of oncoεenes.
For the purposes of the present invention, the term "organism" refers not only to animals, plants, bacteria, viruses, etc. but also to cell cultures, reproduced oligonuncleotides. etc. made from organic material obtained from animals, plants, bacteria, viruses, etc.
For the purposes of the present invention, the term "source well"" refers to any well on a well plate, whether or not the source well contains a sample. For the purposes of the present invention, the term "sample source well" refers to a source well containing a sample.
For the purposes of the present invention, the term "sample" refers to a fluid solution or suspension containing particles to be analyzed using a method and/or apparatus of the present invention. The particles to be analyzed in a sample may be tagged, such as with a fluorescent tag. The particles to be analyzed may also be bound to a bead, a receptor, or other useful protein or polypeptide. or may just be present as free particles, such as particles found naturally in a cell lysate. purified particles from a cell lysate. particles from a tissue culture, etc. The sample may include chemicals, either organic or inorganic, used to produce a reaction with the particles to be analyzed. When the particles to be analyzed are biomaterials. drugs may be added to the samples to cause a reaction or response in the biomaterial particles. The chemicals, drugs or other additives may be added to and mixed with the samples when the samples are in sample source wells or the chemicals, drugs or other additives may be added to the samples in the fluid flow stream after the samples have been intaken by the autosampler.
For the purposes of the present invention, the term "adjacent samples" refers to two samples in a fluid flow stream that are separated from each other by a separation gas. such as an air bubble. For the purposes of the present invention, the term "immediately adjacent samples" refers to adjacent samples that are only separated from each other by a separation gas. For the purposes of the present invention, "buffer fluid separated adjacent samples"' refers to adjacent samples that are separated from each other by two separation gas bubbles and a buffer fluid, with the buffer fluid being located between the two separation gas bubbles.
For the purposes of the present invention, the term "separation gas" refers to any gas such as air, an inert gas. or fluid etc. that can be used to form a gas bubble or immiscible fluid between adjacent samples or between a sample and a buffer fluid. An immiscible fluid is a fluid that will not substantially mix with and contaminate a sample.
For the purposes of the present invention, the term "'buffer fluid" refers to a fluid that is substantially free of the particles to be detected by the apparatus and method of the present invention.
For the purposes of the present invention, the term "drug" refers to any type of substance that is commonly considered a drug. For the purposes of the present invention, a drug may be a substance that acts on the central nervous system of an individual, e.g. a narcotic, hallucinogen, barbiturate, or a psychotropic drug. For the purposes of the present invention, a drug may also be a substance that kills or inactivates disease-causing infectious organisms. In addition, for the purposes of the present invention, a drug may be a substance that affects the activity of a specific cell, bodily organ or function. A drug may be an organic or inorganic chemical, a biomaterial. etc. For the purposes of the present invention, the term "plurality"' refers to two or more of anything, such as a plurality of samples.
For the purposes of the present invention, the term "homogenous" refers to a plurality of identical samples. The term "homogenous" also refers to a plurality of samples that are indistinguishable with respect to a particular property being measured by an apparatus or a method of the present invention.
For the purposes of the present invention, the term "heterogeneous"' refers to a plurality of samples in a fluid flow stream in which there are at least two different types of samples in the fluid flow stream. One way a heterogeneous plurality of samples in a fluid flow stream of the present invention may be obtained is by intaking different samples from different source wells in a well plate. Another way of obtaining a heterogeneous plurality of samples is by intaking different samples from identical source wells at various time points where a reaction or a series of reactions is or had been occurring.
For the purposes of the present invention, the term "fluid flow stream" refers to a stream of fluid samples, separated by one or more bubbles of a separation gas and/or one or more portions of a buffer fluid.
For the purposes of the present invention, the term "fluid flow path" refers to device such as a tube, channel, etc. through which a fluid flow stream flows. A fluid flow path may be composed of several separate devices, such as a number of connected or joined pieces of tubing or a single piece of tubing, alone or in combination with channels or other different devices.
For the purposes of the present invention, the term "high speed multi-sample tube" refers to any tube that may be used with a peristaltic pump that has compression characteristics that allow a peristaltic pump to move samples separated by a separation gas through the tube at a speed of at least 6 samples per minute without causing adjacent samples to mix with each other. An example of such a tube is a polyvinylchloride (PVC) tube having an inner diameter of about 0.01 to 0.03 inches and a wall thickness of about 0.01 to 0.03 inches. A particularly preferred tube is a PVC tube having an inner diameter of about 0.02 inches and a wall thickness of about 0.02 inches.
Description
There have been several efforts at automated sample handling in flow cytometry. For. example, both Coulter Instrument Co. and Becton-Dickinson have sold sample handling systems that use carousels to handle samples from standard sized tubes. These systems typically intake samples at a rate of - 1 tube of sample per minute.
There has also been some effort to intake samples from 96 well plates. For example at the IS AC meeting in 1998 at Colorado Springs, Coulter Instrument Co. showed a TEC AN sampling system for 96 well plates that sampled at about the rate of 3 samples per 2 minutes. Becton-Dickinson is presently developing a system with similar characteristics. Luminex Corp. (Austin, TX) is developing a system that samples at rates of 2-4 samples/minute. It puts a multi-well plate on a movable stage that brings it into position with a syringe controlled sample line.
Other groups have also used valves and syringes in flow cytometry. most notably, the "flow injection" group, Lindberg et al. at University of Washington. One group, Zhao et al. at the University of Minnesota, has recently reported the use of air bubbles in flow cytometry to separate samples. However, in none of the processes described above is there any mention of throughput speed (samples/minute). A group at the University of New Mexico has used plug flow cytometry and achieved sampling rates of at least 6 samples per minute, see U.S. Patent Application No. 09/330.259, the entire disclosure and contents of which is hereby incorporated by reference. Furthermore, in the published descriptions of these processes, the problems with bubbles disrupting flow cytometry were also pointed out. The present invention uses a separation gas. such as air bubbles, to separate samples introduced from an autosampler into a tubing line that directly connects the autosampler and a flow cytometer. A peristaltic pump between the two devices moves the fluid. The air bubbles appear to be most effective at separating samples when there are no junctions or valves in the line. These junctions disturb or break up the bubbles and appear to allow the separated samples to come into contact with one another. Peristaltic flow rates of ~3 ul /second through common tubing (0.02 inch tubing. 10 rpm or higher) have already been determined to be compatible with flow cytometric detection.
Figure 1 A illustrates a preferred flow cytometry apparatus 100 of the present invention. Flow cytometry apparatus 100 includes a conventional autosampler 102 having an adjustable arm 104 on which is mounted a hollow probe 106. As arm 104 moves back and forth (left and right in Figure 1 ) and side to side (into and out of the plane of Figure 1), probe 106 is lowered into individual source wells 108 of a well plate 110 to obtain a sample that has been tagged with a fluorescent tag (not shown in Figure 1) to be analyzed using flow cytometry apparatus 100. Once a sample is picked up by probe 106. a peristaltic pump 112 forces the sample through a tube 114 that extends from autosampler 102 through peristaltic pump 112 and into a flow cytometer 116 including a flow cell 118 and a laser interrogation device 120. Laser interrogation device 120 examines individual samples flowing from flow cell 118 at a laser interrogation point 122. In between intaking sample material from each of source wells 108, probe 106 is allowed to intake air. thereby forming an air bubble between each adjacent sample. Figure IB illustrates series of samples 130, 132 and 134 separated from each other by air bubbles 136 and 138 in tube 114. In Figure IB. sample 130 is immediately adjacent to sample 132. and sample 132 is immediately adjacent to sample 134.
When samples 130. 132 and 134 pass through laser interrogation point 122, the particles in the samples are sensed by flow cytometer 116 due to the fluorescent tag on the particles. In contrast, when air bubbles 136 and 138 pass through laser interrogation point 122. no particles are sensed. Therefore, a graph of the data points of fluorescence sensed versus time for a series of samples analyzed using the flow cytometer of the present invention will form distinct groups, each aligned with the time that a sample containing particles passes through the laser interrogation point. In order to detect the presence of each of two or more different types of samples, in a heterogeneous plurality of samples, each of the two or more different types of samples may be tagged with different fluorescent tags, different amounts of a single tag or some combination of different tags and different amount of a single tag. In such a case, the groupings of data points will vary vertically on a fluorescence versus time graph, depending on which type of sample is being sensed. As with the case of sensing a single type of sample, each sensed sample will exhibit a group of data points aligned with the time that the sample passes through the laser interrogation point.
In an alternative embodiment of the present invention using the flow cytometry apparatus of Figure 1A, some of the source wells on the well plate of the apparatus illustrated in Figure 1A may contain a buffer solution to allow for the formation of buffer fluid separated adjacent samples in a tube through which samples pass. When this is the case, after each sample is picked up by the probe, the probe intakes air. then is lowered into a source well containing buffer solution, then the probe intakes air again, and then the probe intakes a second sample. This sequence may then be repeated for samples which the probe subsequently intakes. Figure 1C shows how two buffer fluid separated adjacent samples 140 and 142 are separated from each other by buffer fluid 144 and two air bubbles 146 and 148 in tube 1 14. When samples 140 and 142 pass through laser interrogation point 122. the particles in the samples are sensed by the flow cytometer due to the fluorescent tag on the particles. In contrast, when buffer fluid 144. and air bubbles 146 and 148 pass through laser interrogation point 122. no particles are sensed. Therefore, a graph of the data points of fluorescence sensed versus time for a series of samples analyzed using the flow cytometer of the present invention will form distinct groups, each aligned with the time that a sample containing particles passes through the laser interrogation point. In order to detect the presence of two or more different types of samples, each of the two or more different types of samples may be tagged with different fluorescence tags or different amounts of a single tag. In such a case, the groupings of data points will vary vertically on a fluorescence versus time graph, depending on which type of sample is being sensed. As with the case of sensing a single type of sample, each sensed sample will exhibit a group of data points aligned with the time that the sample passes through the laser interrogation point.
Alternatively, buffer fluid separated adjacent samples may be formed by providing a reservoir of buffer fluid in or attached to the autosampler to inject buffer fluid into the tube for the fluid flow stream. In this case, after each sample is picked up by the probe, the probe intakes air. then buffer fluid is injected into the tube for the fluid flow stream, then the probe intakes air again, and then the probe intakes a second sample. This sequence may then be repeated for subsequent samples to be separated by a buffer fluid.
The present invention is compatible with relatively inexpensive commercial well plates for use with autosamplers from 96 well plates to 384 well plates to at least as many as 1536 well plates. The source wells of the present invention may be all filled with samples and/or buffer fluids, or some may be left empty. When there are a plurality of different types of samples in the source wells of a well plate, the sample types may be arranged in the order in which they are taken up by the probe, or the sample types may be arranged in any other convenient arrangement. For example, all of the source wells in a one row of source wells may contain one sample type and all of the source wells of a second row may contain a second sample type.
The source wells may be made any conventional shape used for source wells in a well plate for an autosampler. Preferably, when small amounts of sample are used in each source well, the source wells are conical in shape, as illustrated in Figure 1A. to allow even the smallest amounts of sample to be withdrawn by the probe or to allow the particles to concentrate in the bottom of the well. The use of a well plate with conical source wells reduces the problems associated with the settling of particles to the bottom of the well prior to being intaken by the probe. An alternative means to circumvent particle settling would be to sample from wells in an inverted plate given an appropriate well dimensions that will permit sample retention in the well (e.g. by capillary forces) when the plate is in this position. The autosampler of the present invention may be any conventional autosampler suitable for intaking samples from a well plate. A preferred type of autosampler is the Gilson 215 liquid manager.
The use of automation in plate delivery and retrieval for the autosampler may allow automation of the overall screening process.
One preferred probe for the present invention is a .01 inch ID. 1/15 inch OD stainless steel needle compatible with HPLC ferrule fittings. A Gilson interface module for bidirectional communication between an MS DOS computer and a probe manipulating arm and peristaltic pump. Software designed using commercial languages, such as Microsoft Visual C++, may be used to control the speed and distance of probe motions in all 3 dimensions, the sensing of probe contact with liquid in a source well to assure reproducible sample volumes, and the speed of the peristaltic pump. A computer or other known device may be used to control the autosampler to regulate sample size and bubble size by varying the time that the probe is in a source well or above a source well. Also, various sample handlers and sampler handling systems that may be useful in the apparatus and method of the present invention are well known in the art. One example of an integrated handler and programmable station is the Beckman 1000 Laboratory Workstation TM robotic which may be adapted for use in the apparatus or method of the present invention.
In order to reduce carryover, the probe may have a conical tip. Use of silicone or other hydrophobic agent to coat the tip of the sampling probe may also be helpful to minimize sample carryover. Alternatively, the entire probe may be made of a hydrophobic material to reduce carryover. Suitable hydrophobic materials for used in the coating or for making the entire hydrophobic probe include: Teflon® (poly(tetrafluoroethylene) (PTFE)), Kynar ® (polyvinylidene fluoride). Tefzel ® (ethylene-tetrafluoroethylene copolymer). tetrafluoroethylene-perfluoroalkyl vinyl ether copolymer resin (PFA), a tetrafluoroethylene-hexafluoropropylene copolymer (EFP), polyether ether ketone (PEEK), etc.
In order to reduce sample carryover, a jet of gas. such as air, may be sprayed on the tip of the autosampler probe. The source of the jet of gas may be mounted either on the autosampler or near the autosampler. Another way to reduce sample carryover is to use a rinsing device that may be attached to the autosampler or be otherwise mounted on or near the flow cytometry apparatus of the present invention to rinse the autosampler probe between intakes of sample and/or buffer solution. The rinsing fluid may be water, a mild detergent, or a solvent, such as a solvent in which each of the particles in one or more of the samples is dissolved. When the particles are merely suspended in a suspension fluid, the rinsing fluid may be the same as the suspension fluid. The use of an autosampler with a sensing probe tip may improve the efficiency of sample uptake and performance by reducing carryover and ensuring reproducible sample volumes.
Various conventional peristaltic pumps may be used with the flow cytometry apparatus of the present invention. A preferred peristaltic pump is Gilson Minipuls 3. Preferably, a peristaltic pump of the present invention is operated in a manner that reduces pulsatile flow, thereby improving the sample characteristics in the flow cytometer. For example, a tubing length greater than 20 inches between pump and flow cytometer may be used or a linear peristaltic pump such as the Digicare LP5100 may be used to improve the sample characteristics.
Various types of tubing may be used for the fluid flow path of the present invention, as long as the tubing may function as high speed multi-sample tubing. When thin walled PVC (polyvinyl chloride) tubing is used as the tubing for the present invention, carryover between samples is substantially reduced compared to conventional peristaltic tubing. Preferably, the fluid flow path of the present invention is a single length of tubing without junctions. Such a single length of tubing reduces the breakup of bubbles and improves the performance in sample separation. A preferred type of high speed multi-sample tubing for use with the present invention is 0.01 to 0.03 inch inner diameter PVC tubing having a wall thickness of 0.01 to 0.03 inches. A particularly preferred tubing is 0.02 inch inner diameter PVC tubing having a wall thickness of 0.02 inch.
Various types of flow cytometers may be used with the flow cytometry apparatus of the present invention. Preferred types of flow cytometers are described in U.S. Patent Nos. 5.895.764; 5.824,269; 5.395.588; 4.661.913; the entire contents and disclosures of which are hereby incorporated by reference. In the flow cytometer, samples may be sorted on a particle by particle basis using known methods. The flow cytometer may use software gating by light scatter to reduce the "noise" in the flow cytometer introduced by the periodic appearance of bubbles. The use of the real-time software in conjunction with flow cytometer controlling software may allow the samples from a given source well to be re-checked during sampling and data analysis to prove that "hits" from neighboring source wells do not arise from cross-contamination.
On-line data analysis may be used in the flow cytometer to compare data between well plates and facilitate overall utility of the data in conjunction with automation. Operation of the flow cytometer at higher pressure generally increases the sample flow rate and may, in some circumstances yield a higher throughput. Also, operation of the flow cytometer with increased time resolution in data software may allow resolution of samples at higher throughput rates.
Both peristaltic pumps and air bubbles have been used in a variety of detection devices with flowing samples. For example, bubbles are commonly used in clinical instruments to separate samples and the peristaltic pumps to move fluids. However, in flow cytometry there is specific teaching against air bubbles with the idea that, optimally, the bubbles should be removed from the sample prior to injection into the flow cytometer. Using the flow cytometry apparatus of the present invention, it has already been possible to move and analyze at least 6 samples per minute. Preferably, the flow cytometry apparatus may be capable of moving and analyzing 60 samples per minute. even more preferably 120 samples per minute, and yet even more preferably 240 samples per minute.
Among the advantages of the flow cytometer apparatus of the present invention is that it allows rapid sampling of small volumes of sample. For example, a sample drawn into the fluid stream tubing at 10 φm and flowing at a rate of ~3 ul/sec requires less than a 2 ul sample.
The throughput of the flow cytometry apparatus of the present invention tends to be more affected by the behavior of the autosampler rather than the characteristics of the peristaltic pump, the tubing or the flow cytometer. Thus, to the extent that an autosampler can move more rapidly from source well to source well, higher throughputs are achieved. Improved accuracy in volume intake/delivery by the autosampler leads to smaller sample volumes and improved throughputs.
EXAMPLE
Using a flow cytometer apparatus set-up similar to that shown in Figure 1A, commercial peristaltic tubing with thick walls (PharMed TM; 0.02 inch inner diameter. 3.69 mm outer diameter, polypropylene elastomer) was compared with another type (0.02 inch inner and 0.06 inch outer diameter Tygon Microbore TM. formulation S-54- HL) that had thin walls and was considerably stiffer. Figures 2A and 2B illustrate the flow cytometer results using the PharMed TM tubing to move samples 202. 206. 210, and 214 of Coulter Flow-Check beads having a proprietary fluorochrome as a fluorescence tag and four samples 204. 208. 212. and 216 of Flow Cytometry Standards Coφoration having fluorescein as a fluorescence tag. Figure 2A is a graph of Forward Scatter vs. Side Scatter with a gate around the particles aligned in the laser beam of the flow cytometer. Figure 2B is a graph of Fluorescence vs. Time (1024 channels = 60 seconds). The samples in Figure 2 are moved through the tubing using a peristaltic pump operating at 10 RPM. Figures 3 A and 3B illustrate the flow cytometer results using the PVC tubing to move samples 302, 306. 310. and 314 of Coulter Flow-Check beads having a proprietary fluorochrome as a fluorescence tag and four samples 304, 308, 312. and 316 of Flow Cytometry Standards Coφoration beads having fluorescein as a fluorescence tag. Figure 3A is a graph of Forward Scatter vs. Side Scatter with a gate around the particles aligned in the laser beam of the flow cytometer. Figure 3B is a graph of Fluorescence vs. Time (1024 channels = 60 seconds). The samples in Figure 3 are moved through the tubing using a peristaltic pump operating at 10 RPM. As can be seen in Figure 2B and Figure 3B. the grouping of sample data points in Figure 2B exhibit 27% carryover (particles between samples) compared to the groupings of sample data points in Figure 3B that exhibit 5% carryover (particles between samples), indicating that the PVC tubing preserves the integrity of samples better than the PharMed TM tubing does.
Although the present invention has been fully described in conjunction with the preferred embodiments thereof with reference to the accompanying drawings, it is to be understood that various changes and modifications may be apparent to those skilled in the art. Such changes and modifications are to be understood as included within the scope of the present invention as defined by the appended claims, unless they depart therefrom.

Claims

WHAT IS CLAIMED IS:
1. A flow cytometry apparatus for the detection of particles from a plurality of
samples comprising:
means for moving a plurality of samples comprising particles from a plurality of
respective source wells into a fluid flow stream;
means for introducing a separation gas between each of said plurality of samples
in said fluid flow stream; and
means for selectively analyzing each of said plurality of samples for said
particles.
2. The flow cytometry apparatus of claim 1 , wherein said means for moving said
plurality of samples comprises an autosampler.
3. The flow cytometry apparatus of claim 2, wherein said autosampler includes a
probe and said flow cytometry apparatus includes a means for exposing a probe tip of
said probe to a jet of gas to remove liquid from said probe tip.
4. The flow cytometry apparatus of claim 2. wherein said autosampler includes a
probe having a conical tip.
5. The flow
Figure imgf000019_0001
apparatus of claim 2, wherein said autosampler includes a
hydrophobic probe.
6. The flow cytometry apparatus of claim 5. wherein said probe comprises a
hydrophobic material.
7. The flow cytometry apparatus of claim 5, wherein said probe is coated with a
hydrophobic material.
8. The flow cytometry apparatus of claim 2, wherein said means for moving said
plurality of samples further comprises a peristaltic pump.
9. The flow cytometry apparatus of claim 8. wherein a portion of said fluid flow
stream passing through said peristaltic pump is contained within a high speed multi-
sample tube.
10. The flow cytometry apparatus of claim 8, wherein said peristaltic pump is
located along said fluid flow stream between said autosampler and said means for
selectively analyzing said plurality of samples.
1 1. The flow cytometry apparatus of claim 10. further comprising a single length of
tubing extending from said autosampler to said means for selectively analyzing said
plurality of samples.
12. The flow cytometry apparatus of claim 1 1. wherein said single length of tubing
comprises high speed multi-sample tubing.
13. The flow cytometry apparatus of claim 12. wherein said high speed multi-sample
tubing comprises PVC tubing having an inner diameter about 0.01 to about 0.03 inches
and a wall thickness of about 0.01 to about 0.03 inches.
14. The flow cytometry apparatus of claim 12. wherein said high speed multi-sample
tubing comprises PVC tubing having an inner diameter about 0.02 inches and a wall
thickness of about 0.02 inches.
15. The flow cytometry apparatus of claim 1, wherein said separation gas comprises air.
16. The flow cytometry apparatus of claim 1. wherein said plurality of samples are
homogenous.
17. The flow cytometry apparatus of claim 1. wherein said plurality of samples are
heterogeneous.
18. The flow cytometry apparatus of claim 1. wherein said particles comprise
biomaterials.
19. The flow cytometry apparatus of claim 18. wherein said biomaterials are
fluorescently tagged.
20. The flow cytometry apparatus of claim 1. further comprising a well plate
including said plurality of respective source wells.
21. The flow cytometry apparatus of claim 20. wherein said well plate includes at
least 96 source wells.
22. The flow cytometry apparatus of claim 20. wherein said well plate includes at
least 384 source wells.
23. The flow cytometry apparatus of claim 20. wherein said well plate includes at
least 1536 source wells.
24. The flow cytometry apparatus of claim 20. wherein said well plate includes wells
having a conical shape.
25. The flow cytometry apparatus of claim 20. wherein said well plate is mounted in
an inverted position.
26. The flow cytometry apparatus of claim 1. further comprising a means for
injecting a buffer fluid between adjacent samples in said fluid flow stream.
27. The flow cytometry apparatus of claim 1. wherein at least one of said plurality of
samples includes a drug present therein.
28. A method for analyzing a plurality of samples comprising:
moving a plurality of samples comprising particles into a fluid flow stream;
separating adjacent ones of said plurality of samples from each other in said fluid
flow stream by a separation gas; and
selectively analyzing each of said plurality of samples for said particles.
29. The method of claim 28. further comprising intaking said plurality of samples
into said fluid flow stream from a plurality of respective wells.
30. The method of claim 28, wherein said plurality of samples are separated in said
fluid flow stream by intaking air into said fluid flow stream between intaking adjacent
samples of said plurality of samples.
31. The method of claim 28, wherein at least 6 samples are selectively analyzed per
minute.
32. The method of claim 28. wherein at least 60 samples are selectively analyzed per
minute.
33. The method of claim 28. wherein at least 120 samples are selectively analyzed
per minute.
34. The method of claim 28. wherein at least 240 samples are selectively analyzed
per minute.
35. The method of claim 28. wherein said plurality of samples are homogenous.
36. The method of claim 28. wherein said plurality of samples are heterogeneous.
37. The method of claim 28. wherein said particles comprise biomaterials.
38. The method of claim 28, wherein said biomaterials are fluorescently tagged.
39. The method of claim 28. wherein said samples have a sample size ranging from
at least about 0.1 to at least about 10 μl.
40. The method of claim 28 wherein said samples flow in said fluid flow stream at a
flow rate of at least about 0.1 to at least about 10 μl/sec.
41. The method of claim 28. further comprising injecting a buffer fluid between at
least two adjacent samples in said fluid flow stream
79
42. The method of claim 28. by which said plurality of samples are sorted on a
particle by particle basis in a flow cytometer.
43. The method of claim 28. further comprising mixing at least one of said plurality
of samples with at least one drug.
44. The method of claim 43. wherein said at least one drug is mixed with said at
least one of said plurality of samples in a sample source well.
45. The method of claim 43. wherein said at least one drug is mixed with said at
least one of said plurality of samples in said fluid flow stream.
PCT/US2001/006165 2000-02-10 2001-02-09 Flow cytometry for high throughput screening WO2001059429A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001243295A AU2001243295A1 (en) 2000-02-10 2001-02-09 Flow cytometry for high throughput screening

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/501,643 US6890487B1 (en) 1999-09-30 2000-02-10 Flow cytometry for high throughput screening
US09/501,643 2000-02-10

Publications (1)

Publication Number Publication Date
WO2001059429A1 true WO2001059429A1 (en) 2001-08-16

Family

ID=23994430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006165 WO2001059429A1 (en) 2000-02-10 2001-02-09 Flow cytometry for high throughput screening

Country Status (2)

Country Link
AU (1) AU2001243295A1 (en)
WO (1) WO2001059429A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066960A2 (en) * 2001-02-16 2002-08-29 Union Biometrica, Inc. Drug discovery system with auto-sampler for multicellular organisms in a sorting flow cytometer
WO2004020456A2 (en) * 2002-08-28 2004-03-11 Bionexus Ventures L.L.C. Selecting therapeutic human monoclonal antibodies from disease-specific libraries
US7198956B2 (en) 2001-06-13 2007-04-03 Uffenheimer Kenneth F Automated fluid handling system and method
EP1792177A1 (en) * 2004-08-12 2007-06-06 Transform Pharmaceuticals, Inc. Methods for identifiying conditions affecting a cell state
DE102007063440A1 (en) * 2007-12-21 2009-06-25 Thomas Grimm Screening system for analysis of e.g. aerobic and anaerobic biological reactions, has gas chromatograph provided with auto sampler, and reaction container arrangement arranged in function areas of sampler and adapted to size of areas
US7858040B2 (en) 2004-05-07 2010-12-28 Saryna Biotechnologies Llc Direct mixing and injection for high throughput fluidic systems
US20170356836A1 (en) * 2016-06-14 2017-12-14 Intellicyt Method and Apparatus for Decreasing Tubing Carryover With Poly(2-hydroxyethyl methacrylate) Coating
EP3572789A1 (en) 2005-11-04 2019-11-27 Alere Technologies GmbH Device and method for the detection of particles

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053282A (en) * 1976-02-26 1977-10-11 Hach Chemical Company Method and apparatus for sampling impure water
US4116631A (en) * 1976-02-19 1978-09-26 Trinel Pierre Andre Method for microbiological analysis of liquid mediums
US4853336A (en) * 1982-11-15 1989-08-01 Technicon Instruments Corporation Single channel continuous flow system
US5395588A (en) * 1992-12-14 1995-03-07 Becton Dickinson And Company Control of flow cytometer having vacuum fluidics
US5788927A (en) * 1996-07-30 1998-08-04 Bayer Corporation Unified fluid circuit assembly for a clinical hematology instrument
US6132685A (en) * 1998-08-10 2000-10-17 Caliper Technologies Corporation High throughput microfluidic systems and methods
US6150180A (en) * 1996-06-28 2000-11-21 Caliper Technologies Corp. High throughput screening assay systems in microscale fluidic devices
US6156178A (en) * 1999-07-13 2000-12-05 Molecular Dynamics, Inc. Increased throughput analysis of small compounds using multiple temporally spaced injections

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4116631A (en) * 1976-02-19 1978-09-26 Trinel Pierre Andre Method for microbiological analysis of liquid mediums
US4053282A (en) * 1976-02-26 1977-10-11 Hach Chemical Company Method and apparatus for sampling impure water
US4853336A (en) * 1982-11-15 1989-08-01 Technicon Instruments Corporation Single channel continuous flow system
US5395588A (en) * 1992-12-14 1995-03-07 Becton Dickinson And Company Control of flow cytometer having vacuum fluidics
US6150180A (en) * 1996-06-28 2000-11-21 Caliper Technologies Corp. High throughput screening assay systems in microscale fluidic devices
US5788927A (en) * 1996-07-30 1998-08-04 Bayer Corporation Unified fluid circuit assembly for a clinical hematology instrument
US6132685A (en) * 1998-08-10 2000-10-17 Caliper Technologies Corporation High throughput microfluidic systems and methods
US6156178A (en) * 1999-07-13 2000-12-05 Molecular Dynamics, Inc. Increased throughput analysis of small compounds using multiple temporally spaced injections

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066960A3 (en) * 2001-02-16 2003-07-24 Union Biometrica Inc Drug discovery system with auto-sampler for multicellular organisms in a sorting flow cytometer
WO2002066960A2 (en) * 2001-02-16 2002-08-29 Union Biometrica, Inc. Drug discovery system with auto-sampler for multicellular organisms in a sorting flow cytometer
US7198956B2 (en) 2001-06-13 2007-04-03 Uffenheimer Kenneth F Automated fluid handling system and method
US7939017B2 (en) 2001-06-13 2011-05-10 Uffenheimer Kenneth F Automated fluid handling system and method
WO2004020456A2 (en) * 2002-08-28 2004-03-11 Bionexus Ventures L.L.C. Selecting therapeutic human monoclonal antibodies from disease-specific libraries
WO2004020456A3 (en) * 2002-08-28 2004-09-02 Bionexus Ventures L L C Selecting therapeutic human monoclonal antibodies from disease-specific libraries
US7858040B2 (en) 2004-05-07 2010-12-28 Saryna Biotechnologies Llc Direct mixing and injection for high throughput fluidic systems
EP1792177A4 (en) * 2004-08-12 2007-09-19 Transform Pharmaceuticals Inc Methods for identifiying conditions affecting a cell state
EP1792177A1 (en) * 2004-08-12 2007-06-06 Transform Pharmaceuticals, Inc. Methods for identifiying conditions affecting a cell state
EP2336770A1 (en) * 2004-08-12 2011-06-22 Transform Pharmaceuticals, Inc. Methods for identifying conditions affecting a cell state
EP3572789A1 (en) 2005-11-04 2019-11-27 Alere Technologies GmbH Device and method for the detection of particles
DE102007063440A1 (en) * 2007-12-21 2009-06-25 Thomas Grimm Screening system for analysis of e.g. aerobic and anaerobic biological reactions, has gas chromatograph provided with auto sampler, and reaction container arrangement arranged in function areas of sampler and adapted to size of areas
DE102007063440B4 (en) * 2007-12-21 2011-02-17 Thomas Grimm Screening system for the implementation and direct analysis of biological, biochemical and chemical synthesis and reaction reactions
US20170356836A1 (en) * 2016-06-14 2017-12-14 Intellicyt Method and Apparatus for Decreasing Tubing Carryover With Poly(2-hydroxyethyl methacrylate) Coating
WO2017218509A1 (en) * 2016-06-14 2017-12-21 Intellicyt Method and apparatus for decreasing tubing carryover with poly(2-hydroxyethyl methacrylate) coating

Also Published As

Publication number Publication date
AU2001243295A1 (en) 2001-08-20

Similar Documents

Publication Publication Date Title
US9677989B2 (en) Flow cytometry for high throughput screening
EP2313770B1 (en) Multi-sample particle analyzer system and method for high throughput screening
US20030082632A1 (en) Assay method and apparatus
US20030040105A1 (en) Microfluidic micromixer
US10732089B2 (en) Methods and apparatus for real-time detection and clearing of a clog
Ryan et al. Single-cell assays
US20220136949A1 (en) Systems, articles, and methods for flowing particles
US20160320629A1 (en) Fluidic Super Resolution Optical Imaging Systems With Microlens Array
KR20220045160A (en) Systems and Methods for Detection of Separation Gases Between Samples
WO2001059429A1 (en) Flow cytometry for high throughput screening
US20030013201A1 (en) Flow cytometry for high throughput screening
EP0817965A1 (en) Method for identifying biologically active substances by their effect on living cells
US5721135A (en) Apparatus for identifying biologically active substances by their effect on living cells
Schumacher et al. System development for generating homogeneous cell suspensions and transporting them in microfluidic components
US20020142288A1 (en) Auto-sampler for treatment or pretreatment of sample multicellular organisms for a large particle sorting flow cytometer
JP2007075051A (en) Plate for judging biological sample

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10203345

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP